LBT 6.25% 1.5¢ lbt innovations limited

FDA Approval, page-17

  1. 924 Posts.
    lightbulb Created with Sketch. 175
    Thank you, I can help clarify as it appears Bioshares (just curious does anyone know how many subscribers to they have?) haven’t delineated their LBT product research clearly:

    APAS Compact: FDA clearance due anytime now
    APAS Independence: FDA supplementary Clearance due later this year (yet to be submitted) as this covers highly advance automated robotic plate handling technology, sophistically integrated with Hettich’s leading incubation technology to be a potential FMLA killer.

    So let’s focus on near term sales of APAS Compact:

    APAS Compact will be ready to sell this year given FDA asap, and Demo Day at ECCMID on 9th April. The distributor agreement is critical, and when signed, I would expect a USD $25million to $50m USD minimum payment rights to sell the complete LBT APAS range.

    APAS Compact will have a 2 year, first to market lead, according to a HC post citing Bioshares (?) and will penetrate the global microbiology market hard given no comparable FDA cleared product offering.

    A cutting edge independent solution to 27,000 small to medium target market (refer to source table below) for APAS Compact Plate Reader, at an estimated price of US$100,000, means a total ‘potential’ global sales of US $2.7 billion in potential sales.

    LBT can hopefully capture 20% market = LBT revenues of US $540 million over the next 2 years.

    Hopefully Bioshares is right with the 2 year lead!

    Source LBT asx ann:


    LBT market share.png
 
watchlist Created with Sketch. Add LBT (ASX) to my watchlist
(20min delay)
Last
1.5¢
Change
-0.001(6.25%)
Mkt cap ! $23.48M
Open High Low Value Volume
1.5¢ 1.5¢ 1.5¢ $2.1K 140.0K

Buyers (Bids)

No. Vol. Price($)
5 311704 1.5¢
 

Sellers (Offers)

Price($) Vol. No.
1.7¢ 270000 1
View Market Depth
Last trade - 15.36pm 30/07/2024 (20 minute delay) ?
LBT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.